BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
June 6, 2006
View Archived Issues
Tysabri Cleared; FDA Gives 'Very Rare' Second Approval
The FDA is allowing Tysabri to return to the market in a limited capacity for multiple sclerosis patients, three months after an advisory committee voted unanimously in favor of doing so. (BioWorld Today)
Read More
Genelabs' HCV Program Nets Potential $200M Novartis Deal
Read More
Early ASCO Headlines Made By Pharma's Sutent, Tykerb
Read More
Cervarix Showing Promise As Cervical Cancer Field Crowds
Read More
Myogen Starting Phase III For BP-Lowering Drug Darusentan
Read More
Other News To Note
Read More